Suspected adverse drug reactions, principally in
Scandinavia, prompted the EU to suspend marketing authorisation for Econor in
October 2000. A series of extensive investigations were immediately launched by
Novartis Animal Health, which have helped to explain the mysterious findings and
has led to the successful licence reinstatement of the swine antibiotic.
To comment, login here
Or register to be able to comment.